AstraZeneca PLC (AZN)vsNutex Health Inc (NUTX)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
NUTX
Nutex Health Inc
$119.20
+6.41%
HEALTHCARE · Cap: $772.02M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 6611% more annual revenue ($58.74B vs $875.26M). AZN leads profitability with a 17.4% profit margin vs 8.1%. NUTX trades at a lower P/E of 10.6x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
NUTX
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+71.6%
Fair Value
$362.71
Current Price
$119.20
$243.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 59 in profit
Strong operational efficiency at 97.5%
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Revenue declined 41.1%
Earnings declined 86.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : NUTX
The strongest argument for NUTX centers on P/E Ratio, Return on Equity, Operating Margin.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : NUTX
The primary concerns for NUTX are Market Cap, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
NUTX carries more volatility with a beta of 2.02 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 52/100), backed by strong 17.4% margins. NUTX offers better value entry with a 71.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nutex Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?